WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau   

Pub. No.:    WO/2007/088895    International Application No.:    PCT/JP2007/051611
Publication Date: 09.08.2007 International Filing Date: 31.01.2007
C07D 249/14 (2006.01), A61K 31/4196 (2006.01), A61K 31/422 (2006.01), A61K 31/496 (2006.01), A61K 31/5377 (2006.01), A61P 3/04 (2006.01), A61P 3/06 (2006.01), A61P 3/10 (2006.01), A61P 9/10 (2006.01), A61P 9/12 (2006.01), A61P 19/10 (2006.01), A61P 21/00 (2006.01), A61P 21/04 (2006.01), A61P 25/24 (2006.01), A61P 25/28 (2006.01), A61P 27/06 (2006.01), A61P 37/02 (2006.01), A61P 43/00 (2006.01), C07D 401/10 (2006.01), C07D 401/12 (2006.01), C07D 413/10 (2006.01)
Applicants: MOCHIDA PHARMACEUTICAL CO., LTD. [JP/JP]; 7, Yotsuya 1-chome, Shinjuku-ku, Tokyo 1608515 (JP) (For All Designated States Except US).
ITOH, Manabu [JP/JP]; (JP) (For US Only).
OHTA, Masahiko [JP/JP]; (JP) (For US Only).
MIYAZAKI, Yutaka [JP/JP]; (JP) (For US Only).
SAWAMA, Yuka [JP/JP]; (JP) (For US Only).
MATSUMOTO, Shigeki [JP/JP]; (JP) (For US Only).
YAMASAKI, Fumiaki [JP/JP]; (JP) (For US Only)
Inventors: ITOH, Manabu; (JP).
OHTA, Masahiko; (JP).
MIYAZAKI, Yutaka; (JP).
SAWAMA, Yuka; (JP).
MATSUMOTO, Shigeki; (JP).
YAMASAKI, Fumiaki; (JP)
Agent: WATANABE, Mochitoshi; Hayakawa-tonakai Bldg. 3F 12-5, Iwamoto-cho 2-chome Chiyoda-ku, Tokyo 1010032 (JP)
Priority Data:
PCT/JP2006/301586 31.01.2006 JP
2006-207255 28.07.2006 JP
(JA) 3-アリールアミノ-1,2,4-トリアゾール誘導体
Abstract: front page image
(EN)Disclosed is a pharmaceutical composition which is intended to be administered to a patient who needs the inhibition of 11&bgr;-HSD1 or the control of 11&bgr;-HSD1 activity. The pharmaceutical composition comprises a 3-arylamino-1,2,4-triazole derivative represented by the formula (I), a pharmaceutically acceptable salt or prodrug of the derivative, or a solvate of the derivative, salt or prodrug as an active ingredient. The 3-arylamino-1,2,4-triazole derivative is remarkably stable in a human serum and is a highly promising pharmaceutical agent.
(FR)L'invention concerne une composition pharmaceutique susceptible d'être administrée à un patient qui nécessite l'inhibition de 11β-HSD1 ou le contrôle de l'activité de 11β-HSD1. La composition pharmaceutique comprend un dérivé de 3-arylamino-1,2,4-triazole représenté par la formule (I), un sel ou un promédicament du dérivé pharmaceutiquement acceptables, ou un solvate du dérivé, un sel ou un promédicament en tant qu'ingrédient actif. Le dérivé de 3-arylamino-1,2,4-triazole est remarquablement stable dans un sérum humain et constitue un agent pharmaceutique extrêmement prometteur.
(JA) ヒト血清中における安定性が顕著であり、医薬としての高い可能性が期待される、式(I)に示す3-アリールアミノ-1,2,4-トリアゾール誘導体、それらの医薬用許容される塩、プロドラッグまたはそれらの溶媒和物を有効成分として含有する、11β-HSD1の阻害もしくは、11β-HSD1の活性の調節が必要な患者に投与される為の医薬組成物を提供する。
Designated States: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM)
European Patent Office (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).
Publication Language: Japanese (JA)
Filing Language: Japanese (JA)